

Table 11.6a
Immunosuppression Use for Induction, 1999 to 2008
Recipients with Heart Transplants

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Transplants	2,188	2,199	2,202	2,155	2,057	2,015	2,125	2,193	2,209	2,163
With Immunosuppression Info	2,138	2,148	2,152	2,119	2,024	1,974	2,056	2,120	2,152	2,110
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	12.0%	9.4%	7.7%	7.0%	7.9%	7.2%	6.9%	4.7%	4.2%	6.5%
OKT3	11.1%	8.7%	8.6%	5.4%	4.6%	3.6%	3.2%	3.1%	3.2%	1.4%
Thymoglobulin	2.5%	6.9%	10.7%	16.2%	12.9%	15.7%	14.7%	18.2%	19.1%	18.1%
Zenapax	7.2%	8.8%	13.4%	11.4%	14.6%	15.7%	15.6%	14.5%	12.8%	11.1%
Simulect	2.5%	5.1%	5.2%	7.0%	9.3%	10.2%	13.6%	15.0%	14.3%	14.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	1.9%	0.7%	1.7%	2.6%	3.4%
No Induction Drugs Recorded	65.7%	62.8%	56.4%	55.1%	52.9%	52.9%	47.8%	45.2%	46.0%	47.7%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.